Khorana score for prediction of VTE in cancer patients
| Variable . | Points . |
|---|---|
| Site of cancer* | |
| Very high-risk cancer (stomach, pancreas) | 2 |
| High-risk cancer (lung, lymphoma, gynecological, bladder, or testicular) | 1 |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Prechemotherapy hemoglobin level <100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count >11 × 109/L | 1 |
| Body mass index ≥35 kg/m2 | 1 |
| Traditional risk categories | |
| High | ≥3 |
| Intermediate | 1-2 |
| Low | 0 |
| Currently proposed risk categories | |
| Intermediate to high | ≥2 |
| Low | <2 |
| Variable . | Points . |
|---|---|
| Site of cancer* | |
| Very high-risk cancer (stomach, pancreas) | 2 |
| High-risk cancer (lung, lymphoma, gynecological, bladder, or testicular) | 1 |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Prechemotherapy hemoglobin level <100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count >11 × 109/L | 1 |
| Body mass index ≥35 kg/m2 | 1 |
| Traditional risk categories | |
| High | ≥3 |
| Intermediate | 1-2 |
| Low | 0 |
| Currently proposed risk categories | |
| Intermediate to high | ≥2 |
| Low | <2 |
The AVERT trial included brain tumors as very high-risk cancer and myeloma as high-risk cancer.